We made a difficult decision in light of changes in our business strategy on global sales. Our approach to our partner handling the appropriate functions of the business makes sense. As this may have been painful, this will allow us to be focused on the right direction in the long term, and as we are more nimble, we can adjust in this ever changing market. We are will look closely at our US strategy and make the best decisions regarding the current field force. We are examining the right direction with the alignment of our field reps with our partner's strategy. It may be a better and more efficient approach to have AGN led the sales, as having 2 separate distinct sales regiment makes little sense.
What flavor is the koolaid they’re giving you? Were you not here for the last few rounds when everyone said it wouldn’t happen?
Agreed. New pain and bloating data for Linzess, need the reps to pull this through. Not to mention, we are about to pick up a new product and announcement should come very soon.
Because HCPs don’t give us credit for bloating already, right? FWIW endpoint was not bloating, it was the Abdominal Symptom Score (fitting), unlikely we’ll get to talk about bloating. I know the product we’re “bringing in” It’s called DOG. We’ll simply be rumpswab for another company’s waste...
Then LEAVE! Go on now, git! Go find your passion. Although complaining anonymously on cafe pharma is a tremendous use of your time. Douche.
Just waiting on my nice little severance and then this company will be nothing but a bad memory. Looking forward to that and working for a company again that actually has a clue how to run a business - not one that just got lucky with one drug and ran it into the ground with mismanagement, poor leadership and terrible forecasting.
